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dimensional (EQ-5D) utility scores and six-dimensional health state
classiﬁcation (SF-6D) utility scores (derived from the 12-Item Short-
Form Health Survey [SF-12]) by using a large European sample of
patients with stable coronary heart disease. Special attention was
given to country-speciﬁc results. Methods: Data from the EURopean
Action on Secondary and Primary Prevention by Intervention to
Reduce Events III (EUROASPIRE III) survey were used. Patients hospi-
talized for a coronary artery bypass graft, percutaneous coronary
intervention, acute myocardial infarction, or myocardial ischemia
were interviewed and examined at least 6 months after their acute
event. Health-related quality of life was assessed by using the EQ-5D
and the SF-12. SF-12 outcomes were converted to SF-6D utility values,
allowing comparison between both measures. Results: Both EQ-5D
and SF-6D results were available for 7472 patients with coronary heart
disease from 20 European countries. The measures were signiﬁcantly
correlated (intraclass correlation coefﬁcient ¼ 0.536); however, largesee front matter Copyright & 2014, International S
r Inc.
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ondence to: Delphine De Smedt, Ghent University,differences between the two measures remain. A total of 28.8% of the
patients reported a ceiling effect on the EQ-5D instrument, whereas
only 4.2% of the patients reported full health based on the SF-6D.
Especially the mental component does not seem to be completely
captured by the EQ-5D instrument. Furthermore, patients with worse
EQ-5D outcomes were more likely to have better SF-6D results,
whereas patients with better EQ-5D outcomes were more likely to
have worse SF-6D results. Conclusions: Both measures are not inter-
changeable. Whereas the main disadvantage of the EQ-5D question-
naire is its ceiling effect, the potential advantages of SF-12 might
disappear when converting the outcomes into an SF-6D utility,
because of the small differences between patients.
Keywords: coronary heart disease, EQ-5D, health-related quality of life,
SF-12, utility.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Patients’ self-reported health-related quality of life (HRQOL) is
increasingly considered an important outcome of medical treat-
ment, especially in chronic conditions, such as coronary heart
disease (CHD), in which patients are being monitored for a
considerable period of time. CHD is often a cause of pain,
increased anxiety, and functional and social limitations; hence,
patients with CHD are likely to have an impaired HRQOL [1–3].
Many different disease-speciﬁc as well as general measures exist
to assess HRQOL in patients with CHD such as the MacNew Heart
Disease Health-related Quality of Life Questionnaire, the Seattle
Angina Questionnaire, the Myocardial Infarction Dimensional
Assessment Scale, the 36-Item Short-Form Health Survey (SF-
36), the 12-Item Short-Form Health Survey (SF-12), the Health
Utilities Index, and the EuroQol-5D (EQ-5D) questionnaire. Few of
these HRQOL measures, however, generate a single preference-
based utility measure of health. Utilities are particularly useful in
the calculation of incremental cost-effectiveness ratios for com-
puting health beneﬁts expressed in quality-adjusted life-years.
The results of such evaluations enable decision makers to setpriorities with regard to the reimbursement of health care; hence,
the validity of utilities is of great importance. The EQ-5D is the
most commonly used instrument to calculate utilities for cost-
effectiveness analysis purposes. However, an algorithm devel-
oped by Brazier and Roberts in 2004 [4], made it possible to
calculate a utility score based on the SF-12 by converting the
measure into a six-dimensional health state classiﬁcation (SF-6D)
[4–6]. Some concern exists regarding the comparability between
the utility score calculated from the EQ-5D questionnaire and the
one based on the SF-12 [7–10]. A recent study by Joore et al. [11]
reported remarkable differences in cost-effectiveness results
depending on the instrument used. Patients with mild health
conditions had higher EQ-5D scores, whereas patients with
severe conditions had higher SF-6D scores. This leads to better
or worse cost-effectiveness outcomes depending on the HRQOL
instrument used. The incomparability of the results using differ-
ent instruments poses a real threat to the usefulness and
credibility of cost-effectiveness analyses.
Existing literature regarding the comparison of the EQ-5D and
the SF-6D in patients with CHD is scarce. Only one study reported
on this comparison; however, the SF-6D scores were based onociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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[12]. They concluded that the EQ-5D and the SF-6D are quite diffe-
rent from each other in patients with CHD. The aim of the current
study study was to compare the EQ-5D and the SF-6D (based on the
SF-12) utility scores by using a large European sample of patients
with CHD, with an additional focus on country-speciﬁc results.Methods
Coronary Sample
Analyses were based on EURopean Action on Secondary and
Primary Prevention by Intervention to Reduce Events III (EURO-
ASPIRE III) data, a cross-sectional survey performed in 2006-2007
across Europe. More details on this survey can be found else-
where [13]. Brieﬂy, patients aged between 18 and 80 years,
hospitalized for coronary artery bypass graft, percutaneous cor-
onary intervention, acute myocardial infarction, or myocardial
ischemia, were retrospectively identiﬁed from diagnostic regis-
ters, hospital discharge lists, or other sources. In total, 8966
patients (participation rate ¼ 73%) were interviewed and exam-
ined at least 6 months and not later than 3 years after their initial
hospital admission (median time ¼ 1.24 years). During interview,
EQ-5D and SF-12v2 information was collected. HRQOL informa-
tion was available for 20 EUROASPIRE III countries: Belgium,
Bulgaria, Croatia, Cyprus, Czech Republic, Finland, France,
Greece, Ireland, Italy, Latvia, Lithuania, Poland, Romania, Russian
Federation, Slovenia, Spain, The Netherlands, Turkey, and the
United Kingdom. Furthermore, self-reported demographic
details, as well as disease information, were collected by trained
research staff.
HRQOL Instruments
The EQ-5D is a commonly used, easy to complete, standardized
instrument containing a descriptive part and a visual analogue
scale. The former covers ﬁve dimensions, mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression, with
three response categories each (no problems, some problems,
and severe problems). The answers on these dimensions provide
a simple descriptive proﬁle, with 243 possible health states, from
which an index score or utility score can be calculated. Within
the current analyses, we have chosen to use the UK algorithm for
all countries included. To conform to the EuroQoL guidelines, we
used this most robust valuation set, because country-speciﬁc
algorithms were not available for each individual country
included. Theoretically, the index score can range between
0.594 (worst health state) and 1 (full health) [14]. The algorithm
is based on the time trade-off technique developed by Torrance
[15]. With this method, the subject can chose between two
alternatives: a state of illness during a given period followed by
death versus a state of perfect health for a shorter time period
followed by death. The time period is varied until the subject is
indifferent between the two alternatives.
The SF-12v2 is a shortened version of the SF-36, including 12
questions, with three to ﬁve answer categories each (Likert scale).
The instrument covers eight dimensions: general health, physical
functioning, role physical, bodily pain, vitality, social functioning,
role emotional, and mental health. Both a physical functioning
component score and a mental functioning component
score, ranging between 0 and 100, can be calculated by using a
scoring algorithm. Lower scores represent worse and higher
scores represent better self-perceived HRQOL outcomes [16]. By
using an algorithm (UK version) by Brazier et al., SF-6D scores can
be calculated from the SF-12 scores. The SF-6D is based on 11 SF-
12 questions and combines them into six dimensions (physicalfunctioning, role limitations, bodily pain, vitality, social function-
ing, and mental health); 7500 different health states can be
deﬁned, from which an index score or utility score can be
calculated. The score can range between 0.296 and 1 [4–6]. The
algorithm to calculate this score is based on the standard gamble
technique, ﬁrst described by von Neumann and Morgenstern [17].
It is based on a paired comparison in which subjects can chose
between two alternatives. The ﬁrst alternative has two possible
outcomes: either the subject returns to perfect health with
probability P or the subject dies with probability 1  P. The
second alternative leads to a certain disease state for life. The
probability P can be varied until the subject is indifferent between
the two alternatives. Because of the high number of different
health states, many of them are not explicitly evaluated but
estimated on the basis of their proximity to those states that are
tested.Statistical Analyses
Only patients with both EQ-5D and SF-12 information were
included in the analyses. Analyses were performed both on
European and on country-speciﬁc levels. A Wilcoxon signed rank
test was performed to test whether the EQ-5D results differ
signiﬁcantly from the SF-6D values. Furthermore, the Spearman
correlation and the intraclass correlation coefﬁcient between EQ-
5D and SF-6D outcomes and the spearman correlation between
the different dimensions of the EQ-5D and the SF-6D were
calculated. The ceiling effect of both measures was assessed by
estimating the proportion of patients who reported to be in full
health (no problems on either dimension). Analyses were per-
formed by using IBM SPSS version 21.Results
A total of 7472 patients with CHD completed the SF-12 as well as
the EQ-5D instrument. Their mean age was 63.1  9.2 years.
Three quarter of the patients were men, and one in four patients
had received a low education. Almost 60% had a cardiac revas-
cularization as recruiting diagnosis; 23.2% of the patients
reported suffering from diabetes; 4.5% reported a history of
stroke; and 13.3% reported having suffered a recurrent coronary
event since the recruiting diagnosis. Table 1 gives an overview of
the utility outcomes based on the patient characteristics.
Country-speciﬁc results are presented in Table 2. The median
EQ-5D values range between 0.66 (Russia) and 1.00 (Italy) depend-
ing on the country. The lowest EQ-5D value reported was 0.59,
and the highest value was 1.00. About 1.8% of the patients had
EQ-5D outcomes below 0, reﬂecting health states that are per-
ceived worse than death. The median SF-6D values ranged
between 0.66 (Spain, France, Croatia, Lithuania, Poland, Russia,
Slovenia, and Turkey) and 0.80 (Cyprus, Italy, and The Nether-
lands), with the lowest SF-6D value being 0.35 and the highest
being 1.00.
The EQ-5D and the SF-6D seemed to be signiﬁcantly correlated
with an overall Spearman correlation coefﬁcient of 0.695. The
intraclass correlation coefﬁcient, although signiﬁcant, was some-
what lower, with an overall value of 0.536. The correlation
between the different HRQOL dimensions is reported in Table 3.
All dimensions were signiﬁcantly correlated with each other. The
highest correlations are seen between related dimensions such
as physical functioning-mobility (r ¼ 0.446); physical functioning-
usual activities (r ¼ 0.504); role limitation-usual activities (r ¼
0.390); social functioning-usual activities (r ¼ 0.403); pain-pain/
discomfort (r ¼ 0.630); mental health-anxiety/depression (r ¼
0.551).
Table 1 – Utility outcomes by patient characteristics.
EQ-5D SF-6D
All 0.80 (0.69–1.00) 0.70 (0.62–0.82)
Sex
Male 0.80 (0.69–1.00) 0.72 (0.63–0.86)
Female 0.73 (0.62–0.85) 0.66 (0.58–0.74)
Age (y)
o50 0.85 (0.73–1.00) 0.72 (0.64–0.86)
50–59 0.80 (0.69–1.00) 0.72 (0.62–0.86)
60–69 0.80 (0.69–1.00) 0.70 (0.62–0.83)
Z70 0.73 (0.62–0.85) 0.66 (0.61–0.78)
Recruiting diagnosis
CABG 0.80 (0.69–1.00) 0.72 (0.63–0.96)
PCI 0.80 (0.69–1.00) 0.72 (0.62–0.86)
AMI 0.78 (0.66–1.00) 0.66 (0.62–0.80)
Ischemia 0.73 (0.62–0.88) 0.66 (0.60–0.80)
Educational level
Primary 0.74 (0.62–1.00) 0.66 (0.61–0.80)
Secondary 0.80 (0.69–1.00) 0.69 (0.62–0.80)
High 0.81 (0.73–1.00) 0.72 (0.66–0.86)
Diabetes
No 0.80 (0.69–1.00) 0.72 (0.62–0.86)
Yes 0.73 (0.62–0.85) 0.66 (0.60–0.78)
Central obesity
No 0.81 (0.69–1.00) 0.72 (0.63–0.86)
Yes 0.74 (0.64–0.85) 0.66 (0.62–0.80)
Smoking
No 0.80 (0.69–1.00) 0.70 (0.62–0.82)
Yes 0.80 (0.66–1.00) 0.69 (0.62–0.86)
Physical activity
o20 min, 3/wk 0.73 (0.62–0.85) 0.66 (0.60–0.78)
Z20 min, 3/wk 0.80 (0.69–1.00) 0.72 (0.63–0.86)
History of stroke
No 0.80 (0.69–1.00) 0.70 (0.62–0.82)
Yes 0.69 (0.52–0.85) 0.66 (0.57–0.74)
Recurring coronary event
No 0.80 (0.69–1.00) 0.71 (0.62–0.82)
Yes 0.78 (0.66–1.00) 0.66 (0.62–0.80)
Notes. Values are median (IQR). All EQ-5D and SF-6D outcomes are
signiﬁcantly different (Po 0.001), except for patients with a history
of stroke.
AMI, acute myocardial infarction; CABG, coronary artery bypass
graft; EQ-5D, EuroQol ﬁve-dimensional; IQR, interquartile range;
PCI, percutaneous coronary intervention; SF-6D, six-dimensional
health state short form (derived from the 12-Item Short-Form
Health Survey).
 Recurring coronary event after recruiting diagnosis.
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problems on the EQ-5D instrument, whereas only 4.2% (311 of
7472) of the patients reported full health on the SF-6D instru-
ment. Again, some variation was seen across countries, with the
proportion of full health on the EQ-5D instrument ranging from
10.4% (Russia) to 50.9% (Italy); on the SF-6D instrument, full
health was seen in 0.0% (Russia) to 15.7% (Cyprus) of the patients
depending on the country. In those patients with full health on
the EQ-5D, a median SF-6D of 0.86 (interquartile range 0.74–0.92)
was found. Moreover, 15.6% of the patients with a full health
on the EQ-5D still reported an SF-6D value below the overall
median. Patients reporting no limitations on the EQ-5D still
reported substantial problems on the SF-6D role limitation and
vitality dimensions. Furthermore, of those patients reporting
full health on the EQ-5D, 15.5% had a physical component
score-12 value below the overall median and 23.0% had a mentalcomponent score-12 value below the overall median. In contrast,
in those patients with full health on the SF-6D, only 4.2% of the
patients reported an EQ-5D questionnaire value below the over-
all median. Patients with an EQ-5D value below 0 had SF-6D
values ranging between 0.35 and 0.68. Only one patient reported
severe problems on all the EQ-5D questionnaire dimensions,
whereas none of the patients reported the worst possible SF-6D
health state.
Figure 1 compares the EQ-5D utilities with the SF-6D utilities
according to patients’ EQ-5D health proﬁle. According to these
data, patients with worse EQ-5D outcomes were more likely to
have better SF-6D outcomes whereas patients with better EQ-5D
outcomes were more likely to have worse SF-6D results.Discussion
Similar to previous studies in various populations, the EQ-5D
outcomes in patients with CHD are signiﬁcantly correlated with
SF-6D values, with intraclass correlation coefﬁcients indicating
moderate agreement between the instruments [8,10,18]. Moder-
ate correlations were also found between related dimensions.
Correlations found in our study were slightly lower (with the
exception of those related to pain and mental health) than those
reported by Brazier et al. [8] but stronger than those seen by van
Stel and Buskens [12]. There remain, however, signiﬁcant differ-
ences between the EQ-5D and SF-6D utility outcomes. In all
EUROASPIRE III countries, the utility values differed signiﬁcantly
from each other, with median SF-6D utility scores being system-
atically lower than EQ-5D outcomes, both at country-speciﬁc
level and after stratiﬁcation by patient characteristics. Because
of the small sample sizes on the country-speciﬁc level, and the
variability in disease severity and comorbidities, caution is
required when interpreting the results at a country level. It
should also be noted that EQ-5D utility outcomes are based on
UK preference weights, because country-speciﬁc weight were not
available for all included countries.
Furthermore, a ceiling effect was observed in the EQ-5D
instrument, but no ﬂoor effect was seen on either instrument
(although a slight proportion of patients reported EQ-5D out-
comes below 0). These results are similar to previously reported
outcomes [11,12]. One study reported on full health in the
general population, with 47% of the patients having no problems
on the EQ-5D and 5.8% of the patients reporting no problems on
the SF-6D [7]. According to a study by Joore et al. [11], 40% to 54%
of hypertensive patients (depending on the treatment modality)
report full health on the EQ-5D, whereas only 1% to 2% reported
no problems on the SF-6D. A study in patients with CHD found
a ceiling effect on the EQ-5D in 13.5% of the patients, whereas
only 0.4% of the patients reported full health on the SF-6D [12].
Brazier et al. [8] acknowledge a possible ceiling effect of the
EQ-5D and a possible ﬂoor effect of the SF-6D instrument [8].
Subanalyses in the EUROASPIRE III population revealed that
patients reporting no problems on the EQ-5D still reported
substantial problems on the SF-6D role limitation and vitality
dimensions. This is in line with the lower correlations between
the EQ-5D questionnaire dimensions and the SF-6D role limi-
tation and vitality dimensions. Furthermore, within our popula-
tion, mental problems especially are not completely captured by
the EQ-5D instrument. Likewise, in the study by Brazier et al. [8],
based on seven patient groups, it was observed that those
patients in full health on the EQ-5D may still expe-
rience problems in physical functioning, mental health, and
vitality.
As mentioned by others, some of the differences between the
instruments might be explained by the theoretical construction
of the measures [8,9,12]. First, the EQ-5D questionnaire contains
Table 2 – Country-speciﬁc utility outcomes.
Median (IQR) Wilc
test
Spearman
correlation
ICC % (n)
EQ-5D SF-12 EQ-5D
full health
SF-12
full health
Wilc
test
Overall (n ¼ 7472) 0.80 (0.31) 0.70 (0.20) * 0.665* 0.536* 28.8 (2149/7472) 4.2 (311/7472) *
Belgium (n ¼ 246) 0.81 (0.27) 0.72 (0.14) * 0.595* 0.438* 39.0 (96/246) 2.0 (5/246)
Bulgaria (n ¼ 538) 0.80 (0.34) 0.72 (0.25) * 0.688* 0.593* 30.3 (163/538) 7.1 (38/538) *
Cyprus (n ¼ 420) 0.85 (0.27) 0.80 (0.26) * 0.621* 0.528* 37.6 (158/420) 15.7 (66/420) *
Czech Republic
(n ¼ 475)
0.76 (0.19) 0.72 (0.18) * 0.636* 0.515* 24.8 (118/475) 1.3 (6/475) *
Spain (n ¼ 473) 0.76 (0.34) 0.66 (0.20) * 0.679* 0.512* 25.4 (120/473) 3.8 (18/473) *
Finland (n ¼ 237) 0.80 (0.31) 0.72 (0.24) * 0.644* 0.518* 29.1 (69/237) 3.0 (7/237) *
France (n ¼ 269) 0.73 (0.18) 0.66 (0.14) * 0.572* 0.430* 17.8 (48/269) 0.7 (2/269)
UK (n ¼ 277) 0.80 (0.31) 0.72 (0.25) * 0.720* 0.583* 29.6 (82/277) 2.2 (6/277) †
Greece (n ¼ 119) 0.85 (0.31) 0.72 (0.20) * 0.605* 0.513* 35.3 (42/119) 7.6 (9/119) *
Croatia (n ¼ 437) 0.73 (0.23) 0.66 (0.17) * 0.670* 0.518* 22.7 (99/437) 2.5 (11/437) *
Ireland (n ¼ 370) 0.85 (0.27) 0.78 (0.21) * 0.713* 0.620* 39.2 (145/370) 4.6 (17/370) *
Italy (n ¼ 377) 1.00 (0.20) 0.80 (0.26) * 0.634* 0.519* 50.9 (192/377) 4.5 (17/377) *
Lithuania (n ¼ 505) 0.74 (0.19) 0.66 (0.18) * 0.583* 0.464* 20.4 (103/505) 1.8 (9/505) †
Latvia (n ¼ 518) 0.85 (0.27) 0.74 (0.23) * 0.503* 0.422* 39.6 (205/518) 8.1 (42/518) *
The Netherlands
(n ¼ 199)
0.85 (0.27) 0.80 (0.25) * 0.664* 0.607* 42.2 (84/199) 10.1 (20/199) *
Poland (n ¼ 461) 0.73 (0.23) 0.66 (0.14) * 0.651* 0.489* 20.4 (94/461) 0.7 (3/461) *
Romania (n ¼ 521) 0.76 (0.19) 0.68 (0.18) * 0.649* 0.504* 24.6 (128/521) 3.3 (17/521) *
Russia (n ¼ 405) 0.66 (0.15) 0.66 (0.14) † 0.698* 0.494* 10.4 (42/405) 0.0 (0/521)
Slovenia (n ¼ 292) 0.69 (0.33) 0.66 (0.15) † 0.688* 0.485* 14.7 (43/292) 2.7 (8/292) *
Turkey (n ¼ 333) 0.81 (0.31) 0.66 (0.13) * 0.689* 0.456* 35.4 (118/333) 3.0 (10/333) *
EQ-5D, EuroQol ﬁve-dimensional; ICC, intraclass correlation coefﬁcient; IQR, interquartile range; SF-6D, six-dimensional health state short
form (derived from the 12-Item Short-Form Health Survey); Wilc test, Wilcoxon signed rank test.
 P o 0.01.
† P o 0.05.
Table 3 – Correlation between EQ-5D questionnaire and SF-12 (SF-6D) dimensions.
Physical functioning Role limitation Social functioning Pain Mental health Vitality
Mobility 0.446 0.338 0.346 0.459 0.268 0.325
Self-care 0.318 0.223 0.313 0.321 0.230 0.247
Usual activities 0.504 0.390 0.403 0.474 0.321 0.371
Pain/discomfort 0.415 0.395 0.390 0.630 0.354 0.343
Anxiety/depression 0.281 0.405 0.410 0.338 0.551 0.324
Notes. All correlations are signiﬁcant (P o 0.001). Bold indicates related dimensions.
EQ-5D, EuroQol ﬁve-dimensional; SF-6D, six-dimensional health state short form (derived from the 12-Item Short-Form Health Survey).
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sions. In addition, the recall period is different: “today” versus
“past four weeks”; however, we agree with van Stel and Buskens
[12] that the inﬂuence of the recall period in the utility differences
might be nonsigniﬁcant because HRQOL was measured in
patients with stable CHD (6 months to 3 years after the recruiting
diagnosis) [12]. Furthermore, the EQ-5D questionnaire covers ﬁve
dimensions, each with three answer categories, whereas the SF-
6D is based on 11 SF-12 questions, each with three to ﬁve
response categories. An increase in the number of questions
and answers automatically leads to a more descriptive and
sensitive tool with a higher amount of possible outcomes. A
patient who sometimes has frightened feelings might, for exam-
ple, indicate that he or she is not anxious or depressed on the EQ-
5D questionnaire, whereas on the SF-12 he or she would indicate
“a little of the time” on the question whether he or she has felt
downhearted and depressed. This is only one example indicatingthe more reﬁned answer options of the SF-12. Conversion from
the SF-12 to the SF-6D, however, is associated with some
sensitivity loss, particularly due to the small range of possible
utility scores. The SF-6D outcomes range between 0.296 and 1,
which is almost half of the possible EQ-5D questionnaire range;
hence, SF-6D outcomes are more centered to the middle and the
potential difference between health states is larger when using
the EQ-5D utility scores. This was also reported in an article by
McDonough and Tosteson [19], concluding that cost-effectiveness
analyses using the SF-6D give less favorable cost-effectiveness
results [19]. The EQ-5D outcomes, however, are very much
skewed to the right; hence, the probability of having worse
outcomes is rather low, and therefore the room for improvement
is limited, especially in patients with a mild or largely asympto-
matic condition. In contrast, the impairments associated with a
mild condition might be better recognized by the SF-6D; hence,
the SF-6D might be more sensitive for smaller impairments,
Fig. 1 – Comparison between EQ-5D utilities and SF-6D utilities according to patients’ EQ-5D health proﬁle. EQ-5D, EuroQol
ﬁve-dimensional; SF-6D, six-dimensional health state short form (derived from the 12-Item Short-Form Health Survey).
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in utility score rather than the absolute value of the score is of
most importance in cost-effectiveness analyses.
In agreement with the literature, EUROASPIRE III results have
indicated that patients with worse EQ-5D outcomes were more
likely to have better SF-6D results, whereas patients with better
EQ-5D outcomes were more likely to have worse SF-6D results
[11]. Furthermore, our results indicate that disease severity or
patient characteristics are not always equally captured by both
instruments. In patients with diabetes, a history of stroke, or a
recurrent coronary event, the proportion of patients reporting full
health is lower, both using the EQ-5D and the SF-6D. Patients who
are categorized as having a coronary artery bypass graft or
percutaneous coronary intervention, however, were more likely
to report full health on the EQ-5D but not on the SF-6D compared
to patients having acute myocardial infarction or ischemia. Like-
wise, smokers and obese patients were less likely to report full
health on the SF-6D but not on the EQ-5D questionnaire than
were nonsmokers and patients with a normal weight.
Medicine has changed tremendously during the last century.
New scientiﬁc insights have led to the development of several
innovations regarding medication, technical procedures, and
diagnostic tools. Today’s society strives to provide the best
possible health care; however, ﬁnancial resources are limited.
Therefore, the use of cost-effectiveness analyses is becoming
increasingly important. Current recommendations from the
National Institute for Health and Care Excellence promote the
use of the EQ-5D questionnaire instrument for the calculation of
quality-adjusted life-years [20]. It is important, however, to
recognize the advantages and disadvantages of both the EQ-5D
questionnaire and the SF-6D instrument. Although the main
disadvantage of the EQ-5D questionnaire is its ceiling effect, the
potential advantages of the SF-12 might disappear when con-
verting the outcomes into an SF-6D utility score. The new ﬁve-
level EQ-5D questionnaire might overcome some of the above-
reported problems by increasing sensitivity and reducing the
ceiling effects; however, further research is needed to investigate
these issues [21].
In conclusion, our study results have indicated that both
utility tools are not interchangeable. In addition to the different
theoretical construction of the instruments and the unequal
utility range, differences in outcome can be explained by patient
characteristics and disease severity. Knowledge of these incon-
sistencies is required when using utility values to avoid compar-
ison of values derived from different instruments.Acknowledgments
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